Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
Possible Side Effects
Common Side Effects (Dose-Dependent):
- Nausea (20-47% with monotherapy, higher with CagriSema)
- Constipation (common due to slowed gastric emptying)
- Vomiting (less common than with GLP-1 agonists alone)
- Diarrhea
- Abdominal pain
- Injection site reactions
Less Common Side Effects:
- Decreased appetite
- Dyspepsia
- Fatigue
- Dizziness
- Headache
Rare but Serious Side Effects:
- Acute cholelithiasis (gallstones)
- Pancreatitis (theoretical risk)
- Severe hypoglycemia (when combined with insulin or sulfonylureas)
Note: Most GI side effects are transient, mild-to-moderate, and improve with continued use.
Possible Side Effects
Common Side Effects (Dose-Dependent):
- Nausea (20-47% with monotherapy, higher with CagriSema)
- Constipation (common due to slowed gastric emptying)
- Vomiting (less common than with GLP-1 agonists alone)
- Diarrhea
- Abdominal pain
- Injection site reactions
Less Common Side Effects:
- Decreased appetite
- Dyspepsia
- Fatigue
- Dizziness
- Headache
Rare but Serious Side Effects:
- Acute cholelithiasis (gallstones)
- Pancreatitis (theoretical risk)
- Severe hypoglycemia (when combined with insulin or sulfonylureas)
Note: Most GI side effects are transient, mild-to-moderate, and improve with continued use.
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.